Literature DB >> 25410057

Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I.

Jonathan M Heppner1, Frank Zaucke2, Lorne A Clarke3.   

Abstract

Progressive skeletal and connective tissue disease represents a significant clinical burden in all of the mucopolysaccharidoses. Despite the introduction of enzyme replacement strategies for many of the mucopolysaccharidoses, symptomatology related to bone and joint disease appears to be recalcitrant to current therapies. In order to address these unmet medical needs a clearer understanding of skeletal and connective tissue disease pathogenesis is required. Historically the pathogenesis of the mucopolysaccharidoses has been assumed to directly relate to progressive storage of glycosaminoglycans. It is now apparent for many lysosomal storage disorders that more complex pathogenic mechanisms underlie patients' clinical symptoms. We have used proteomic and genome wide expression studies in the murine mucopolysaccharidosis I model to identify early pathogenic events occurring in micro-dissected growth plate tissue. Studies were conducted using 3 and 5-week-old mice thus representing a time at which no obvious morphological changes of bone or joints have taken place. An unbiased iTRAQ differential proteomic approach was used to identify candidates followed by validation with multiple reaction monitoring mass spectrometry and immunohistochemistry. These studies reveal significant decreases in six key structural and signaling extracellular matrix proteins; biglycan, fibromodulin, PRELP, type I collagen, lactotransferrin, and SERPINF1. Genome-wide expression studies in embryonic day 13.5 limb cartilage and 5 week growth plate cartilage followed by specific gene candidate qPCR studies in the 5week growth plate identified fourteen significantly deregulated mRNAs (Adamts12, Aspn, Chad, Col2a1, Col9a1, Hapln4, Lum, Matn1, Mmp3, Ogn, Omd, P4ha2, Prelp, and Rab32). The involvement of biglycan, PRELP and fibromodulin; all members of the small leucine repeat proteoglycan family is intriguing, as this protein family is implicated in the pathogenesis of late onset osteoarthritis. Taken as a whole, our data indicates that alteration of the extracellular matrix represents a very early event in the pathogenesis of the mucopolysaccharidoses and implies that biomechanical failure of chondro-osseous tissue may underlie progressive bone and joint disease symptoms. These findings have important therapeutic implications.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arthritis; Extracellular matrix structural integrity; MPS I; MRM; SLRPs; iTRAQ

Mesh:

Substances:

Year:  2014        PMID: 25410057     DOI: 10.1016/j.ymgme.2014.09.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

Review 1.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Convergent molecular mechanisms underlying cognitive impairment in mucopolysaccharidosis type II.

Authors:  Thiago Corrêa; Fabiano Poswar; Cíntia B Santos-Rebouças
Journal:  Metab Brain Dis       Date:  2021-11-19       Impact factor: 3.655

Review 3.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

4.  12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.

Authors:  Orazio Gabrielli; Lorne A Clarke; Anna Ficcadenti; Lucia Santoro; Lucia Zampini; Nicola Volpi; Giovanni V Coppa
Journal:  BMC Med Genet       Date:  2016-03-10       Impact factor: 2.103

5.  Characterization of the MPS I-H knock-in mouse reveals increased femoral biomechanical integrity with compromised material strength and altered bone geometry.

Authors:  Arin K Oestreich; Mekka R Garcia; Xiaomei Yao; Ferris M Pfeiffer; Sabah Nobakhti; Sandra J Shefelbine; Yong Wang; Amanda C Brodeur; Charlotte L Phillips
Journal:  Mol Genet Metab Rep       Date:  2015-09-07

6.  Targeting Heparan Sulfate Proteoglycans as a Novel Therapeutic Strategy for Mucopolysaccharidoses.

Authors:  Valeria De Pasquale; Patrizia Sarogni; Valeria Pistorio; Giuliana Cerulo; Simona Paladino; Luigi Michele Pavone
Journal:  Mol Ther Methods Clin Dev       Date:  2018-06-18       Impact factor: 6.698

7.  Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III).

Authors:  Nicole M Muschol; Daniel Pape; Kai Kossow; Kurt Ullrich; Laila Arash-Kaps; Julia B Hennermann; Ralf Stücker; Sandra R Breyer
Journal:  Orphanet J Rare Dis       Date:  2019-05-02       Impact factor: 4.123

8.  Comparative analysis of gene expression profiles in normal hip human cartilage and cartilage from patients with necrosis of the femoral head.

Authors:  Ruiyu Liu; Qi Liu; Kunzheng Wang; Xiaoqian Dang; Feng Zhang
Journal:  Arthritis Res Ther       Date:  2016-05-04       Impact factor: 5.156

Review 9.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

10.  Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.

Authors:  Abhijit Ricky Pal; Jean Mercer; Simon A Jones; Iain A Bruce; Brian W Bigger
Journal:  PLoS One       Date:  2018-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.